SOLID TUMOURS

BARCODE

ORDER FORM

HEALTH CARE PROVIDER INFORMATION

INSTITUTION/PRACTICE	ADDRESS (STREET NAME, NO., CITY, POSTCODE, COUNTRY)
FIRST NAME	TELEPHONE NUMBER (COUNTRY CODE & NUMBER)
LAST NAME	E-MAIL ADDRESS (FOR REPORT ACCESS)

PATIENT INFORMATION

FIRST NAME	ADDRESS (STREET NAME, NO., CITY, POSTCODE, COUNTRY)
LAST NAME	TELEPHONE NUMBER (COUNTRY CODE & NUMBER)
DATE OF BIRTH (DD/MM/YYYY)	IDENTIFICATION NO. (IF APPLICABLE)

GENETIC SEX ☐ FEMALE ☐ MALE
☐ OTHER (SPECIFY KARYOTYPE IF KNOWN):

CLINICAL INFORMATION

Cancer type:_____

Stage ☐ Primary / ☐ Metastatic (if metastases are present, list site of metastases:_____)

Comprehensive information on the clinical history and diagnosis is essential for interpreting genetic findings and making recommendations for drug therapy. Please provide any relevant information, if available; e.g., pathology reports (histopathology, immunohistochemistry) and the patient's clinical history:

SAMPLE MATERIAL

The quality of laboratory test results is highly dependent on specimen quality and tumour cell content. Tumour cell content in the submitted or marked tissue area must be >20%.

Slides are accepted but are not preferred. When submitting slides, at least 7 unstained tissue sections of 10 µm on nonSuperfrost™ Plus slides and 8 unstained tissue sections of 5 µm on Superfrost™ Plus slides are required. Do not place coverslips on the unstained slides.

FFPE tissue block (preferred sample type):

FFPE tissue block ID:_____ Percentage of tumour cells in the specimen:_____ Collection date:_____

Please provide one slide with a HE-stained tissue section and mark the tumour area for macrodissection, if necessary.

Slides with unstained tissue sections:

Number of slides:_____ FFPE tissue block ID:_____ Percentage of tumour cells in the specimen:_____

Collection date:_____

Please provide one additional slide with a HE-stained tissue section and mark the tumour area for macrodissection, if necessary.

MVZ Martinsried GmbH
Lochhamer Str.29, 82152 Martinsried, Germany
www.medicover-genetics.com

SOLID TUMOURS

BARCODE

TEST REQUEST

☐ **00617 Solid tumour comprehensive molecular profiling** *(Based on OncoDEEP® NGS technology; the assay analyses 638 DNA genes and 22 RNA driver genes, providing a complete view of genomic alterations and key biomarkers such as HRD, MSI, and TMB)*

☐ **00652 Solid tumour – rearrangement analysis** *(ALK, ROS1, RET, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, BRAF, NRG1, EWSR1, TMPRSS2)*

TUMOUR-SPECIFIC TARGETED TESTS

Please note: For each tumour type, the targeted analysis includes all applicable dedicated analyses listed for that tumour type. To order an individual analysis only, please select the corresponding dedicated test.

☐ **00536 BREAST CANCER – targeted analysis**
- ☐ 00709 Sequencing analysis *(BRCA1, BRCA2, ERBB2, PIK3CA, PTEN)*
- ☐ 00707 Fusion gene analysis *(NTRK1, NTRK2, NTRK3, RET)*
- ☐ 00708 Microsatellite instability testing (MSI)

☐ **00535 COLORECTAL CANCER (CRC) – targeted analysis**
- ☐ 00705 Sequencing analysis *(BRAF, KRAS, NRAS, POLE)*
- ☐ 00702 Fusion gene analysis *(NTRK1, NTRK2, NTRK3, RET)*
- ☐ 00703 Microsatellite instability testing (MSI)
- ☐ 00704 MLH1 promoter methylation analysis *(MLH1)*

☐ **00532 ENDOMETRIAL CANCER – targeted analysis**
- ☐ 00694 Sequencing analysis *(POLE, TP53)*
- ☐ 00692 Fusion gene analysis *(NTRK1, NTRK2, NTRK3)*
- ☐ 00693 Microsatellite instability testing (MSI)
- ☐ 00706 MLH1 promoter methylation analysis *(MLH1)*

☐ **00614 GASTROINTESTINAL STROMAL TUMOURS (GIST) – targeted analysis**
- ☐ 00697 Sequencing analysis *(BRAF, KIT, NF1, PDGFRA, SDHA)*
- ☐ 00695 Fusion gene analysis *(FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3)*
- ☐ 00696 Microsatellite instability testing (MSI)

☐ **00534 GLIOBLASTOMA – targeted analysis**
- ☐ 00701 Sequencing analysis *(IDH1, IDH2, TERT)*
- ☐ 00698 Fusion gene analysis *(NTRK1, NTRK2, NTRK3)*
- ☐ 00700 Microsatellite instability testing (MSI)
- ☐ 00699 MGMT promoter methylation analysis *(MGMT)*

☐ **00537 MALIGNANT MELANOMA – targeted analysis**
- ☐ 00713 Sequencing analysis *(BRAF, KIT, NRAS)*
- ☐ 00711 Fusion gene analysis *(ALK, BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1)*
- ☐ 00712 Microsatellite instability testing (MSI)

☐ **00538 NON–SMALL CELL LUNG CANCER (NSCLC) – targeted analysis**
- ☐ 00716 Sequencing analysis *(BRAF, EGFR, ERBB2, KRAS)*
- ☐ 00714 Fusion gene analysis *(ALK, NTRK1, NTRK2, NTRK3, RET, ROS1)*
- ☐ 00715 Microsatellite instability testing (MSI)

☐ **00539 OVARIAN CANCER – targeted analysis**
- ☐ 00730 Sequencing analysis *(BRAF, BRCA1, BRCA2)*
- ☐ 00728 Fusion gene analysis *(NTRK1, NTRK2, NTRK3, RET)*
- ☐ 00729 Microsatellite instability testing (MSI)

☐ **00540 PANCREATIC CANCER- targeted analysis**
- ☐ 00741 Sequencing analysis *(BRAF, BRCA1, BRCA2, KRAS, PALB2)*
- ☐ 00745 Fusion gene analysis *(ALK, FGFR2, NTRK1, NTRK2, NTRK3, RET, ROS1)*
- ☐ 00744 Microsatellite instability testing (MSI)

☐ **00541 PROSTATE CANCER – targeted analysis**
- ☐ 00751 Sequencing analysis *(ATM, BRAF, BRCA1, BRCA2, CHEK2, FANCA, PALB2, RAD51D)*
- ☐ 00749 Fusion gene analysis *(NTRK1, NTRK2, NTRK3)*
- ☐ 00750 Microsatellite instability testing (MSI)

☐ **00763 THYROID CANCER – targeted analysis**
- ☐ 00765 Sequencing analysis *(BRAF, RET)*
- ☐ 00760 Fusion gene analysis *(ALK, NTRK1, NTRK2, NTRK3, RET, ROS1)*
- ☐ 00764 Microsatellite instability testing (MSI)

☐ **00542 UROTHELIAL CANCER – targeted analysis**
- ☐ 00758 Sequencing analysis *(ERBB2, FGFR2, FGFR3, PIK3CA)*
- ☐ 00756 Fusion gene analysis *(NTRK1, NTRK2, NTRK3)*
- ☐ 00757 Microsatellite instability testing (MSI)

For further information on specific tests and/or gene content, please visit our website: www.medicover-genetics.com.
If you have additional questions or concerns, please contact us at info.genetics@medicover.com

MEDICOVER GENETICS

MVZ Martinsried GmbH
Lochhamer Str.29, 82152 Martinsried, Germany
www.medicover-genetics.com

ONCO-SOLIDTMR-OF-V6-10/26